Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease that leads to scarring of the lungs, a process known as fibrosis. New research demonstrates that blocking a protein called interleukin-11 (IL-11) using therapeutic antibodies can actually reverse this destructive process.